ライフサイエンスコーパス: thrombospondin

1 , alphavbeta3, GPIbalpha, tissue factor, and thrombospondin.

2 he annexin A6/LDL receptor-related protein 1/thrombospondin 1 (ANXA6/LRP1/TSP1) complex in tumor cell

3 Human thrombospondin 1 (hTSP-1) is a matricellular glycoprotei

4 ARID domain-dependent, BAF-A associations at THROMBOSPONDIN 1 (THBS1) led to the concomitant upregula

5 Thrombospondin 1 (THBS1) was recently shown to promote b

6 Thrombospondin 1 (THBS1), a circulating adipokine, incre

7 ased expression of an anti-angiogenic factor thrombospondin 1 (Tsp-1) and decreased expression of two

8 aneous somatic Ca2+ transients, synaptogenic thrombospondin 1 (TSP-1) release, and synapse formation.

9 Basal muscle expression of thrombospondin 1 (TSP-1) was approximately 900% greater

10 ial growth factor (VEGF), but high levels of thrombospondin 1 (TSP-1), predicted liver dysfunction af

11 le expressed significantly reduced levels of thrombospondin 1 (TSP1) (P = 0.042) and increased levels

12 Thrombospondin 1 (TSP1) has been suggested as a counter

13 /-) manifested higher expression of CTGF and thrombospondin 1 (TSP1).

14 s 1, IV and XVIII as well as fibronectin and thrombospondin 1 (TSP1).

15 responsible for binding to LRP1, whereas the thrombospondin 1 and spacer domains are responsible in A

16 ion of the powerful angiostatic glycoprotein Thrombospondin 1 independently of Beclin 1 transcription

17 imal glands of C57BL/6J [wild type (WT)] and thrombospondin 1 null (TSP1(-/-), alias Thbs1(-/-)) mice

18 2), MMP9 (matrix metallopeptidase 9), TSP1 (thrombospondin 1), etc.

19 l fibroblasts through the down-regulation of thrombospondin 1, a latent transforming growth factor-be

20 ncluding vascular endothelial growth factor, thrombospondin 1, connective tissue growth factor, hepat

21 Additionally, malaria pathogenicity genes (thrombospondin 1-(THBS 1), interleukin 6 (IL6), and argi

22 , GFAP, inducible nitric oxide synthase, and thrombospondins 1 and 2 in DS astroglia.

23 The human matricellular glycoprotein thrombospondin-1 (hTSP-1) is released by activated plate

24 ical PspC molecule, with human matricellular thrombospondin-1 (hTSP-1).

25 rotein containing the CD36 binding domain of thrombospondin-1 (known as the TSR domain) induced assoc

26 l metalloprotease (M), disintegrin-like (D), thrombospondin-1 (T), Cys-rich (C), and spacer (S) domai

27 h metalloprotease (M), disintegrin-like (D), thrombospondin-1 (T), Cys-rich (C), and spacer (S) domai

28 , metalloprotease (M), disintegrin-like (D), thrombospondin-1 (T), Cys-rich (C), and spacer (S) domai

29 on of the TGF-beta-regulated biomarker genes thrombospondin-1 (THBS1) and cartilage oligomeric protei

30 Strikingly, thrombospondin-1 (Thbs1) ranked as the most differential

31 c study focused on the matricellular protein Thrombospondin-1 (THBS1) to uncover molecular mechanisms

32 We examined thrombospondin-1 (THBS1, alias TSP-1) expression in huma

33 EC-AGO1 suppression results in inhibition of thrombospondin-1 (THBS1/TSP1), an antiangiogenic and pro

34 eptidomimetic of the anti-angiogenic protein thrombospondin-1 (TSP-1 PM).

35 have recently been reported to complex with thrombospondin-1 (TSP-1) in specialized structures terme

36 Thrombospondin-1 (TSP-1) inhibits growth factor signalin

37 Thrombospondin-1 (TSP-1) is a glycoprotein considered as

38 Thrombospondin-1 (TSP-1) is a large extracellular matrix

39 Thrombospondin-1 (TSP-1) is an endogenous inhibitor of a

40 Here we show TGF-beta activation by thrombospondin-1 (TSP-1) is both required and sufficient

41 Thrombospondin-1 (TSP-1) is one of the anti-angiogenic f

42 Increasing evidence suggests thrombospondin-1 (TSP-1), a potent proatherogenic matric

43 nd re-expression of a synaptogenic molecule, thrombospondin-1 (TSP-1), apart from supporting neuronal

44 spectrometry helped pinpoint this factor as thrombospondin-1 (TSP-1).

45 ic destruction of the antitumorigenic factor thrombospondin-1 (Tsp-1).

46 on of a key secreted anti-angiogenic factor, thrombospondin-1 (Tsp-1).

47 ts high levels of the angiogenesis inhibitor thrombospondin-1 (TSP-1).

48 One protein that can activate TGFbeta1 is thrombospondin-1 (TSP-1).

49 -regulated STAT3 phosphorylation, astrocytic thrombospondin-1 (TSP1) and synaptic low-density lipopro

50 njury via a mechanism mediated by astrocytic thrombospondin-1 (TSP1) and synaptic low-density lipopro

51 The N-terminal thrombospondin-1 (TSP1) domain forms an unexpectedly ext

52 lted in upregulation of the synaptogenic cue thrombospondin-1 (TSP1) in astrocytes, increased excitat

53 We confirm upregulation of thrombospondin-1 (TSP1) in Id cDKO hearts.

54 s calcineurin/NFATc1-dependent expression of thrombospondin-1 (Tsp1) in lung endothelial cells to dri

55 Thrombospondin-1 (TSP1) inhibits angiogenesis, in part,

56 Thrombospondin-1 (TSP1) is a multifunctional matricellul

57 that, upon CREB activation, HDAC2 represses thrombospondin-1 (TSP1), a potent angiogenesis inhibitor

58 ited tumor angiogenesis via the induction of Thrombospondin-1 (TSP1), and consequently suppressed tum

59 by JHDM1D-mediated epigenetic regulation of thrombospondin-1 (TSP1), forming a JHDM1D/TSP1/TGF-beta/

60 he hypothesis that the matricellular protein thrombospondin-1 (TSP1), through binding to and activati

61 essed TGF-beta expression, and an inhibitory thrombospondin-1 (Tsp1)-based peptide inhibited chlamydi

62 A SIRP-alpha antibody that blocks thrombospondin-1 activation of SIRP-alpha mitigated the

63 AME, the guanylyl cyclase inhibitors ODQ and thrombospondin-1 also abated IR-induced IL10 expression

64 Thrombospondin-1 also stimulated phosphorylation of p47(

65 CD47 is a signaling receptor for thrombospondin-1 and an attractive therapeutic target be

66 ncreased expression levels of antiangiogenic thrombospondin-1 and inhibited S1177 phosphorylation of

67 We have previously reported that the protein thrombospondin-1 and its receptor CD47 are induced in AK

68 Therefore, thrombospondin-1 and its receptor CD47 may be useful tar

69 at least in part through down-regulation of thrombospondin-1 and plasminogen activator inhibitor typ

70 Here, we report a novel interaction between thrombospondin-1 and SIRP-alpha on nonphagocytic cells.

71 focal adhesion signaling, as well as reduced thrombospondin-1 and TGF-beta1.

72 can also be heterotypic-for example, between thrombospondin-1 and thrombospondin-5.

73 Binding studies with isolated human thrombospondin-1 and various Hic domains suggest that th

74 al cells returned the antiangiogenic protein thrombospondin-1 as a common target of both miRNAs.

75 g identified a carboxyl-terminal fragment of thrombospondin-1 as an unexpected SMAP component that co

76 Overall, these results suggest that thrombospondin-1 binding to SIRP-alpha on nonphagocytic

77 In cell-free experiments, thrombospondin-1 bound SIRP-alpha.

78 The thrombospondin-1 concentrations in ST-Elevation Myocardi

79 These data demonstrate that thrombospondin-1 exerts CD47-dependent and -independent

80 Only the CD47-binding domain of thrombospondin-1 exhibits this activity.

81 We have uncovered a novel role of thrombospondin-1 in modulating production and activation

82 In rodent aortic rings, treatment with thrombospondin-1 increased the production of superoxide

83 CD47, CD36, and integrin-binding domains of thrombospondin-1 independently enhance the inflammasome-

84 Thrombospondin-1 is a glycoprotein with multiple biologi

85 ed previously that the matricellular protein thrombospondin-1 is upregulated in IRI.

86 nal tubular epithelial cells, treatment with thrombospondin-1 led to phosphorylation of SIRP-alpha an

87 Serum thrombospondin-1 level was significantly increased after

88 Physiological concentrations of thrombospondin-1 limit the induction by lipopolysacchari

89 Disintegrin-like and Metalloproteinase with Thrombospondin-1 motifs) protein family, cleaves large p

90 marrow-derived macrophages that lack either thrombospondin-1 or CD47 exhibit diminished induction of

91 Blockade of thrombospondin-1 or CD47 provides local radioprotection

92 M organization, we find that accumulation of thrombospondin-1 or thrombospondin-5 puncta within cell-

93 e evolved from cell-SELEX that can recognize thrombospondin-1 protein in human plasma samples.

94 design of an M55-aptasensor for quantifying thrombospondin-1 protein in plasma samples.

95 Thrombospondin-1 regulates inflammation by engaging seve

96 13 (a disintegrin and metalloproteinase with thrombospondin-1 repeats, member 13), identifying critic

97 py resolved a cytotoxic core surrounded by a thrombospondin-1 shell of ~120 nanometer diameter.

98 nhibition can be explained by the ability of thrombospondin-1 to disrupt the interaction between CD47

99 Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy

100 EOC cells with a recombinant version of the thrombospondin-1 type I repeats (3TSR) induced more apop

101 The KD value of the aptamer M55 binding to thrombospondin-1 was determined as 0.5 +/- 0.2 muM with

102 ty group box-1 protein, chemokine CXCL4, and thrombospondin-1 were significantly higher in patients w

103 endothelial growth factor) and lower TSP-1 (thrombospondin-1) levels than control BEC; and that micr

104 argo, including von Willebrand factor (VWF), thrombospondin-1, and platelet factor 4.

105 lasma levels of von Willebrand factor (VWF), thrombospondin-1, myeloperoxidase, ADAMTS-13, and active

106 d messenger RNA expression of interleukin-6, thrombospondin-1, plasminogen activator inhibitor-1, and

107 Furthermore, the endogenous ligand thrombospondin-1, responsible for the synaptogenic prope

108 -regulated the potent angiogenesis inhibitor thrombospondin-1, thereby triggering a negative feedback

109 tein expression of anti-angiogenic peptides (thrombospondin-1, TSP-1; and endostatin) as well as pro-

110 curred alongside down-regulation of CD47 and thrombospondin-1, which are known to exert SIRP-alpha cr

111 mia-reperfusion injury is exacerbated by the thrombospondin-1-CD47 system through inhibition of nitri

112 is study, we investigate the function of the thrombospondin-1-like glycoprotein, Nel (neural epiderma

113 Renal IRI upregulated the thrombospondin-1-SIRP-alpha signaling axis and was assoc

114 CD47 is a receptor for the secreted protein thrombospondin-1.

115 um factors, namely von Willebrand factor and thrombospondin-1.

116 eins, including vitronectin, CD40-ligand and thrombospondin-1.

117 and (3) a stimulatory role for thrombin, the thrombospondin-1/CD36 axis and cyclooxygenase 1 in subse

118 aimed to mimic the trimeric structure of the thrombospondin-1/CD47 binding epitope.

119 on injury (IRI), which is exacerbated by the thrombospondin-1/CD47 pathway through inhibition of nitr

120 Hydrogen peroxide reduced thrombospondin 2 (an MMP-3 suppressor) expression in pro

121 increased across all patient samples include Thrombospondin 2 (THBS2), encoding a matricellular prote

122 study, we explored whether the expression of thrombospondin 2 (TSP2), a matricellular protein with a

123 a-1; tenascin C; collagen, type VI, alpha-3; thrombospondin 2; and von Willebrand factor) were verifi

124 transforming growth factor beta1 and beta2; thrombospondin 2; intercellular adhesion molecule 1; int

125 levels of gamma-H2AX, cleaved caspase-3, and thrombospondin-2 (THBS2) implicated in apoptosis.

126 in vivo efficacy of intraluminal delivery of thrombospondin-2 (TSP-2) small interfering RNA (siRNA).

127 is regulated by multiple factors, including thrombospondin-2 (TSP2) and hypoxia/VEGF-induced activat

128 CM) abnormality to the bleeding diathesis in thrombospondin-2 (TSP2) knockout (KO) mice.

129 Intraluminal delivery of thrombospondin-2 small interfering RNA inhibits the vasc

130 alpha2delta-1 and the synaptogenic domain of thrombospondin-2 was prevented by gabapentin.

131 idence interval: 1.06 to 1.79; p = 0.02] for thrombospondin-2).

132 everal of the proteins, including Nt-proBNP, thrombospondin-2, interleukin-18 receptor, gelsolin, and

133 d newly emergent biomarkers, angiopoietin-2, thrombospondin-2, latent transforming growth factor-beta

134 Two proteins, angiopoietin-2 and thrombospondin-2, were associated with HF in 3 separate

135 rminal proB-type natriuretic peptide], TSP2 [thrombospondin-2], MBL [mannose-binding lectin]; and 3 w

136 y, NFIA directly regulates the expression of thrombospondin 4 (Thbs4) in the SVZ, revealing a key tra

137 -generated astrocytes express high levels of thrombospondin 4 (Thbs4), a secreted homopentameric glyc

138 eracts with the extracellular matrix protein thrombospondin 4 (TSP4), and antibodies to TSP4 neutrali

139 Mass spectrometry revealed that thrombospondin-4 (THBS4) and SPARC-like protein 1 (SPARC

140 We recently reported that thrombospondin-4 (Thbs4) has a critical intracellular fu

141 Here we show that Thrombospondin-4 (Thbs4) regulates skeletal muscle integ

142 We found that in endothelial cells (EC) thrombospondin-4 (TSP-4), a secreted extracellular matri

143 nerve injury induces increased expression of thrombospondin-4 (TSP4) in spinal cord and dorsal root g

144 Thrombospondin-4 (TSP4) is a pro-angiogenic protein that

145 ion of a novel neuropathic pain contributor, thrombospondin-4 (TSP4), using a neuropathic pain model

146 oprecipitation could be demonstrated between thrombospondin-4 and alpha2delta-1 when co-transfected,

147 Thrombospondin-4 expression was reduced at the mRNA leve

148 Matrilin-1, matrilin-4, epiphycan, and thrombospondin-4 levels were reduced in collagen IX null

149 We concentrated on thrombospondin-4, because, like alpha2delta-1, it is upr

150 Matrilin-4, collagen XII, thrombospondin-4, fibronectin, betaig-h3, and epiphycan

151 cells co-transfected with alpha2delta-1 and thrombospondin-4, there was a Mg(2+) -dependent reductio

152 but there was no co-immunoprecipitation with thrombospondin-4-EGF domain.

153 reproduced by the synaptogenic EGF-domain of thrombospondin-4.

154 XCL10xwomen (0.69), and the interaction term thrombospondin 4xmen (1.38).

155 3825807 has an effect on ADAMTS7 maturation, thrombospondin-5 cleavage, and VSMC migration, with the

156 ind that accumulation of thrombospondin-1 or thrombospondin-5 puncta within cell-derived ECM is contr

157 in (WGA) reactive glycans on fibronectin and thrombospondin-5 were preferentially bound by multimers

158 notype contained less of the cleaved form of thrombospondin-5, an ADAMTS7 substrate that had been sho

159 ic-for example, between thrombospondin-1 and thrombospondin-5.

160 d from anabolic remodeling linked to maximal thrombospondin and platelet-derived growth factor D expr

161 MTS-5 identified that the noncatalytic first thrombospondin and spacer domains mediate its endocytosi

162 duced expression of fibronectin, N-cadherin, thrombospondin, and the notch ligand jagged-1 in culture

163 ules, such as ECM metalloproteinase inducer, thrombospondins, and integrins, can further mediate cell

164 We have reported that astrocyte-secreted thrombospondins, and their target neuronal receptors (al

165 Thrombospondins are a family of stress-inducible secrete

166 disintegrin-like and metalloproteinase with thrombospondin) are a family of proteinases that are str

167 In investigating how thrombospondins become retained within ECM and thereby a

168 al microscopy revealed that fibrin(ogen) and thrombospondin colocalized as "cap," a single patch on t

169 n and metalloproteinase" (ADAMs), ADAMs with thrombospondin domains (ADAM-TS), and Astacins are now r

170 For ADAMs with ThromboSpondin domains (ADAMTSs), there are biological a

171 or hUTC-secreted synaptogenic factors as the thrombospondin family proteins (TSPs), TSP1, TSP2, and T

172 holipase I, ras homolog family member B, and thrombospondin-I [TSP1]) and hypothesized that their uri

173 proteins with new ones emerging (collagen-I, thrombospondin-I, plasminogen activator inhibitor, MMP1,

174 ccumulation and thereby the functionality of thrombospondins in ECM.

175 pleiotropic functions, including adhesion to thrombospondin, inhibition of angiogenesis, transport of

176 lta-1 on feeding and implicate alpha2delta-1-thrombospondin interactions known to facilitate excitato

177 The incorporation of thrombospondins into extracellular matrix (ECM) as discr

178 ovel, conserved, surface-exposed site on the thrombospondin L-type lectin domain.

179 e alpha AOA genomes harbour genes encoding a thrombospondin-like outer membrane structure that probab

180 repeat domain, and a C terminus containing a thrombospondin-like type I repeat (TSR) domain.

181 This site acts to recruit thrombospondin molecules into ECM by intermolecular inte

182 s), a disintegrin and metalloproteinase with thrombospondin motif (ADAMTS) and the tissue inhibitors

183 (a disintegrin and metalloproteinase with a thrombospondin motif repeats 13) has antithrombotic prop

184 as a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) metalloproteinases that m

185 ns, a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS), modulates structural pla

186 teinase (MMP)-13, a disintegrin and MMP with thrombospondin motifs (ADAMTS)-4, and type II collagen e

187 and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTSs).

188 ), adamalysins (ADAMs), and adamalysins with thrombospondin motifs (ADAMTSs).

189 A disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13) cleaves von Willebra

190 A disintegrin and metalloprotease with thrombospondin motifs 13 (ADAMTS13) is a metalloprotease

191 13 (a disintegrin and metalloproteinase with thrombospondin motifs 13) caused a dose-dependent reduct

192 ase a disintegrin and metalloproteinase with thrombospondin motifs 3 (ADAMTS3) and the secreted facto

193 fying a disintegrin and metalloprotease with thrombospondin motifs 4 (ADAMTS4) and miR-322 as potenti

194 3-, a disintegrin and metalloproteinase with thrombospondin motifs 4-, matrix metalloproteinase (MMP)

195 Adamalysin-like metalloproteinase with thrombospondin motifs 5 (ADAMTS-5) is a major aggrecan-d

196 and a disintegrin and metalloproteinase with thrombospondin motifs 5 and of the inflammatory factors

197 zyme, adamalysin-like metalloproteinase with thrombospondin motifs 5.

198 led a disintegrin and metalloproteinase with thrombospondin motifs [ADAMTS]) is responsible for endog

199 TS (a disintegrin and metalloproteinase with thrombospondin motifs) and BMP1 (bone morphogenetic prot

200 -5 (A disintegrin and metalloproteinase with thrombospondin motifs) degrades aggrecan, a proteoglycan

201 TS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) enzymes are secreted, multi-domai

202 TS (a disintegrin and metalloproteinase with thrombospondin motifs) family contribute to the cataboli

203 (A Disintegrin-like and Metalloprotease with Thrombospondin motifs) genes as central component of the

204 16 (a disintegrin and metalloproteinase with thrombospondin motifs) is a secreted mammalian metallopr

205 disintegrin-like and metalloproteinase with thrombospondin motifs, 16, a member of a family of multi

206 ntify A disintegrin and metalloprotease with thrombospondin motifs-3 as a VEGF-C-activating protease

207 y the A disintegrin and metalloprotease with thrombospondin motifs-3 protease, resulting in the matur

208 and a disintegrin and metalloproteinase with thrombospondin motifs-4 (ADAMTS-4) and ADAMTS-5 are cons

209 A disintegrin and metalloproteinase with thrombospondin motifs-4 (ADAMTS-4) and ADAMTS-5 are zinc

210 disintegrin-like and metalloproteinase with thrombospondin motifs-4) is a secreted proteinase involv

211 ron increased the amount of fibrin(ogen) and thrombospondin on the surface of the PS-positive platele

212 wth factor beta (TGF-beta) through a ligand, thrombospondin one (TSP-1).

213 Thrombospondins participate in many aspects of tissue or

214 alpha2delta-1, a calcium channel subunit and thrombospondin receptor, in triggering overeating in mic

215 erythrocytic antigen insert multiple epitope-thrombospondin-related adhesion protein (ME-TRAP).

216 red with the vaccine candidate P. falciparum thrombospondin-related adhesion protein (PfTRAP) express

217 48-, sporozoite-specific protein 20318-325-, thrombospondin-related adhesion protein (TRAP) 130-138-,

218 he other inducing potent T-cell responses to thrombospondin-related adhesion protein (TRAP) by using

219 her subunit vaccines, such as virus-vectored thrombospondin-related adhesive protein (TRAP), provide

220 Microneme protein 2 (MIC2), a member of the thrombospondin-related anonymous protein (TRAP) family,

221 mune responses against Plasmodium falciparum thrombospondin-related anonymous protein (TRAP) in clini

222 protein (CSP), liver stage antigen 1 (LSA1), thrombospondin-related anonymous protein (TRAP), and cel

223 Surface-associated TRAP (thrombospondin-related anonymous protein) family protein

224 containing sporozoite-specific protein named thrombospondin-releated protein 1 (TRP1) is important fo

225 that the sporozoite protein with an altered thrombospondin repeat (SPATR) is a micronemal protein co

226 dhesin of T. gondii, has highly glycosylated thrombospondin repeat (TSR) domains.

227 ied a disintegrin and metalloproteinase with thrombospondin repeat 7 (ADAMTS7) as a CTGF binding prot

228 the AP convertase is mediated by a single FP thrombospondin repeat and a small region in C3b.

229 that contains 19 NANP repeats followed by a thrombospondin repeat domain.

230 von Willebrand factor A (VWA) domain and six thrombospondin repeat domains (TSR1-6) in its ectodomain

231 We found that a thrombospondin-repeat containing sporozoite-specific pro

232 in metalloproteinases (ADAMs) and ADAMs with thrombospondin repeats (ADAMTSs) play a crucial role in

233 AMTS (a disintegrin and metalloprotease with thrombospondin repeats)-like family, a class of extracel

234 ACLP contains thrombospondin repeats, a collagen-binding discoidin dom

235 Glycoproteins (eg, thrombospondins, secreted protein acidic and rich in cys

236 spondins, with the interaction involving the thrombospondin synaptogenic domain and the alpha2delta-1

237 Thrombospondins (Thbs) are a family of five secreted mat

238 shorter N-MADD-4B form, which comprises four thrombospondin (TSP) domains and one Ig-like domain and

239 Extracellular matrix proteins from the thrombospondin (TSP) family have been identified as liga

240 We identified 7 O-fucosylation sites in the thrombospondin (TSP) type 1 repeats.

241 eract through integrin (Itg) ligands such as Thrombospondin (Tsp), while vertebrate muscles attach to

242 rpose of this study was to determine whether thrombospondin (TSP)-1 promotes macrophage activity and

243 that the prototypical matricellular protein thrombospondin (TSP)-1, a potent angiostatic molecule an

244 We show for the first time that a vertebrate thrombospondin, Tsp4b, is essential for muscle attachmen

245 is is mediated in part by astrocyte-released thrombospondins (TSPs) and activation of their neuronal

246 Thrombospondins (TSPs) are secreted extracellular matrix

247 Moreover, we identified thrombospondins (TSPs) as the hUTC-secreted factors that

248 Astrocyte-secreted thrombospondins (TSPs) induce the formation of structura

249 Gabapentin antagonizes the interaction of thrombospondins (TSPs) with the alpha2delta-1 receptor,

250 omprising, in addition to IGFBP and vWC, the thrombospondin type 1 (TSP1) repeats are CCN1 degradome

251 d structure containing subdomain homology to thrombospondin type 1 and interleukin (IL)-13 receptor (

252 eptor 1 (PLA2R1) and the recently identified thrombospondin type 1 domain-containing 7A (THSD7A) are

253 Thrombospondin type 1 domain-containing 7A (THSD7A) is a

254 Thrombospondin type 1 domain-containing 7A (THSD7A) is a

255 ropathy have autoantibodies directed against thrombospondin type 1 domain-containing 7A (THSD7A), a p

256 type phospholipase A2 receptor 1 (PLA2R) and thrombospondin type 1 domain-containing 7A (THSD7A).

257 (GBM), phospholipase A2 receptor (PLA2R) and thrombospondin type 1 domain-containing 7A are target an

258 tor, Fibronectin Type 3, Immunoglobulin, and Thrombospondin type 1 domains, which are collectively pr

259 egrin-like and metalloproteinase domain with thrombospondin type 1 motif (ADAMTS) proteases is requir

260 essed A Disintegrin And Metalloprotease with ThromboSpondin type 1 motif 13 (ADAMTS13)-derived peptid

261 egrin-like and Metalloproteinase domain with Thrombospondin type 1 Motif)-1, -4 and -5 share the abil

262 d (3) a disintegrin and metalloprotease with thrombospondin type 1 motif, 13 (ADAMTS13) activity >10%

263 such as ADAMTS13 (ADAM metallopeptidase with thrombospondin type 1 motif, 13) for coronary artery dis

264 disintegrin-like and metalloproteinase with thrombospondin type 1 motif, member 13 (ADAMTS13) revolu

265 f a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13).

266 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) activity (>10%).

267 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), also known as v

268 13 (a disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13), cleavage by whi

269 (a disintegrin and metalloproteinase, with a thrombospondin type 1 motif, member 13), resulting in fo

270 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).

271 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; the endogenous V

272 and metalloproteinase (reprolysin type) with thrombospondin type 1 motifs) proteins are necessary for

273 he FGF inhibitory activity was mapped to the thrombospondin type 1 region, contrasting the known func

274 ose is added to cysteine-rich domains called thrombospondin type 1 repeats (TSRs) by protein O-fucosy

275 Thrombospondin type 1 repeats (TSRs) occur in diverse pr

276 d both C-mannosylated and non-C-mannosylated thrombospondin type 1 repeats (TSRs) of netrin receptor

277 cose disaccharide to a consensus sequence in thrombospondin type 1 repeats (TSRs) of several proteins

278 eta1-3fucose disaccharide to properly folded thrombospondin type 1 repeats (TSRs).

279 ER quality control mechanism for folding of thrombospondin type 1 repeats by protein O-fucosyltransf

280 TS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats member 13) prevents microv

281 C-Mannosylation is a common modification of thrombospondin type 1 repeats present in metazoans and r

282 icted epidermal growth factor domain and two thrombospondin type 1 repeats, implying a role in host c

283 TS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) proteolysis of

284 TS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13), the specific

285 n and A Disintegrin and Metalloprotease with Thrombospondin type 1 repeats-13 (ADAMTS-13) to 60%, 24%

286 s a common posttranslational modification of thrombospondin type 1 repeats.

287 (a disintegrin and metalloproteinase with a thrombospondin type I motif, member 13).

288 ld in binding to the membrane proximal sixth thrombospondin type I repeat domain of MIC2.

289 MIC2 contains six thrombospondin type I repeats (TSRs) that are modified b

290 disintegrin-like and metalloproteinase with thrombospondin type I repeats 13) accounts for this proc

291 The phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-containing 7A (THSD7A) are

292 Mass spectrometry identified this antigen as thrombospondin type-1 domain-containing 7A (THSD7A).

293 ntegrin-like and metalloprotease domain with thrombospondin type-1 motif, number 13) on secretion fro

294 13 (a disintegrin and metalloproteinase with thrombospondin type-1 motif-13).

295 ADAMTSL2 contains seven thrombospondin type-1 repeats (TSRs), six of which conta

296 eas a disintegrin and metalloproteinase with thrombospondin type-1 repeats 13 (ADAMTS-13) cleaves VWF

297 TS13 (a disintegrin and metalloprotease with thrombospondin type-1 repeats)-mediated proteolysis.

298 date, little is known about the diversity of thrombospondin-type-1 repeat (TSR) domain proteins in ba

299 We therefore examined whether interaction of thrombospondin with alpha2delta-1 might reciprocally inf

300 alpha2delta-1 was identified as a ligand of thrombospondins, with the interaction involving the thro